Document is current

Article History

Received: 5 November 2025

Accepted: 28 December 2025

First Online: 6 January 2026

Declarations

:

: The study was performed after receiving approval by the ethics committee (Comité de Protection des Personnes Île-de-France III).

: Not applicable. The data was aggregated. No individual or identifiable participant data are included.

: During the execution of this study, Baxter Healthcare Corporation was the Sponsor. Baxter’s Kidney Care segment is now Vantive Healthcare. The results presented in this paper have not been submitted previously in whole or in part, except in abstracts and poster form for ISICEM 2025 and SCCM 2026. JK, KH, WM, and RP are employees of Vantive Healthcare. JG was a consultant for Baxter Healthcare Corporation at the time the study was conducted. AC, SJ, BL, RT, AMD, TD, FU, VC, JM, and JMF were principal investigators in this clinical trial. They received no funding from Baxter or Vantive beyond this role, with trial support paid to their institution. This publication was subject to review by internal employees from Vantive prior to submission for accuracy and protection of Confidential Information. However, the Authors retain full responsibility for the content of this publication. AC reports honoraria for lectures from Getinge and Baxter outside of the submitted work. The rest of the authors declare that they have no competing interests.